Entera Bio Ltd. (ENTX): Cash & Equivalents
$7.11M
As of 2025-12-31
$11.31M
As of 2026-06-30
-16.7%
3-year compound annual growth
-3.7%
5-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $7.11M | -17.9% | 2026-03-27, Balance as of period end |
| 2024-12-31 | $8.66M | -21.4% | 2026-03-27, Balance as of period end |
| 2023-12-31 | $11.02M | -10.5% | 2025-03-28, Balance as of period end |
| 2022-12-31 | $12.31M | -50.6% | 2024-03-08, Balance as of period end |
| 2021-12-31 | $24.89M | +189.7% | 2023-03-31, Balance as of period end |
| 2020-12-31 | $8.59M | n/a | 2022-03-08, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Entera Bio Ltd. (ENTX) | 2025-12-31 | $7.11M | -17.9% |
| Inmune Bio, Inc. (INMB) | 2025-12-31 | $24.75M | +18.3% |
| Senti Biosciences Holdings, Inc. (SNTI) | 2025-12-31 | $16.42M | -66.0% |
| AIM ImmunoTech Inc. (AIM) | 2025-12-31 | $2.98M | +75.5% |
| VivoSim Labs, Inc. (VIVS) | 2026-03-31 | $5.02M | -55.6% |
| aTYR PHARMA INC (ATYR) | 2025-12-31 | $10.74M | -2.8% |
| Cardiff Oncology, Inc. (CRDF) | 2025-12-31 | $17.47M | -66.1% |
| ImageneBio, Inc. (IMA) | 2025-12-31 | $94.53M | +680.1% |
| Prokidney Corp. (PROK) | 2025-12-31 | $108.54M | +9.5% |
Compare ENTX, INMB, SNTI, AIM side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗